Trial results for liraglutide in adolescents with Type 1 diabetes were posted on ClinicalTrials.gov on 2025-04-20. The study showed that liraglutide treatment reduced the mean total daily insulin dose from 0.97 U/kg/day to 0.67 U/kg/day. Additionally, the mean number of hypoglycemic episodes (< 70 mg/dL) decreased from 5.5 to 3.3 during treatment.
Background
Liraglutide is a glucagon-like peptide agonist. Type 1 diabetes is an autoimmune disease typically diagnosed before the age of 20, where individuals are entirely dependent on insulin for survival. Despite technological advancements, insulin remains the sole effective treatment for Type 1 diabetes.
Trial design
The study (NCT02516657) was a Phase 3 trial that enrolled 5 participants. It investigated the effect of liraglutide in adolescents with Type 1 diabetes. The study aimed to evaluate the impact of liraglutide on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses. Participants served as their own controls, with measurements taken before and during liraglutide treatment.
Key results
The trial reported several key measurements comparing conditions before and during liraglutide treatment:
- Total Daily Insulin Dose: Before liraglutide, the mean dose was 0.97 U/kg/day (Standard Deviation: 0.18). During liraglutide treatment, the mean dose decreased to 0.67 U/kg/day (Standard Deviation: 0.14).
- Blood Sugar < 70 mg/dL (hypoglycemic episodes): Before liraglutide, participants experienced a mean of 5.5 episodes (Standard Deviation: 7.7). During liraglutide treatment, this decreased to a mean of 3.3 episodes (Standard Deviation: 3.3).
- Mean Weekly Blood Glucose: For the liraglutide 0.6 mg group, mean weekly blood glucose levels were reported as 187 mg/dL (Standard Deviation: 35) and 178 mg/dL (Standard Deviation: 42) at different measurement points.
- Serum Amylase Level: Before liraglutide, the mean level was 36 U/L (Standard Deviation: 15). During liraglutide treatment, the mean level was 33 U/L (Standard Deviation: 11).
What this means
The results from this Phase 3 trial suggest that liraglutide treatment in adolescents with Type 1 diabetes may lead to a reduction in the total daily insulin dose required. The observed decrease in hypoglycemic episodes is also a potentially beneficial outcome. These findings could have implications for managing Type 1 diabetes in adolescents, potentially offering a way to reduce insulin burden and improve glycemic control, though the small enrollment size of 5 participants warrants cautious interpretation.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT02516657, titled "Liraglutide in Adolescents With Type 1 Diabetes," were posted on 2025-04-20 on clinicaltrials.gov.